US Medical Affairs

Quantitative hepatitis B surface antigen (qHBsAg) is a useful biomarker for CHB^1,2
What is qHBsAg and functional cure?
How does qHBsAg at baseline predict treatment outcomes?
How can qHBsAg be used in response-guided therapy?
How can qHBsAg predict risk of relapse after stopping NA treatment?
How can qHBsAg be used in contemporary studies?

Quantitative hepatitis B surface antigen (qHBsAg) is a useful biomarker for CHB^1,2

qHBsAg can help to predict clinical outcomes and response to treatment^1,2

Woman sitting on stairs

US Medical Affairs

Getting ahead of liver disease together

Footnotes & Abbrev

Close

Virological relapse is defined as detectable HBV DNA>2000 IU/ml
Biochemical response is defined as ALT ≥2xULN

ALT, alanine aminotransferase; anti-HBsAb, anti-hepatitis B surface antibody; cccDNA, covalently closed circular DNA; CHB, chronic hepatitis B; DNA, deoxyribonucleic acid; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; IU, international unit; NA, nucleoside analogue; Peg-IFN, pegylated interferon; qHBsAg, quantitative hepatitis B surface antigen; SVR, sustained virological response.
Home
References
Close
1. Vachon A, Osiowy C. Viruses 2021;13:951.
2. Lok J, et al. Aliment Pharmacol Ther 2022;56:760–76.
3. Hu J, et al. Viruses 2017;9:56.
4. Testoni B, et al. Semin Liver Dis 2017;37:231–42.
5. Tseng TC, et al. Aliment Pharmacol Ther 2015;41:949–60.
6. Downs LO, et al. mBio 2019;10:e00699-19.
7. Wong RJ, et al. J Viral Hepatol 2017;24:1089–97.
8. Liaw YF. Hepatology 2011;53:2121–9.
9. Coffin CS, et al. Viruses 2022;14:2668.
10. Sonneveld MJ, et al. Hepatology 2010;52:1251–7.
11. Sonneveld MJ, et al. Hepatology 2013;58:872–80.
12. Rijckborst V, et al. Hepatology 2010;52:454–61.
13. Rijckborst V, et al. J Hepatol 2012;56:1006–11.
14. van Bömmel F, et al. J Hepatol 2023;78:926–36.
15. Lim SG, et al. J Hepatol 2022;77(S1):S869.
16. Lim SG, et al. Poster No. 3117 presented at International Liver Congress™ 2022 (European Association for the Study of the Liver), 22–26 June 2022, London, United Kingdom
17. Mak LY, et al. Clin Mol Hepatol 2023;29:263–76.
18. Terrault NA, et al. Hepatology 2022;75:709–23.

Getting ahead of liver disease together

This educational content has been developed and sponsored by
GSK Medical Affairs and it is intended for Healthcare Professionals only.
© 2001-2023 GSK plc. All rights reserved.
GSK is a registered trademark of GSK plc.

PSE-US-2040 August 2023